These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17940488)

  • 1. Hypereosinophilic syndrome: diagnosis and treatment.
    Peros-Golubicić T; Smojver-Jezek S
    Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
    Gotlib J
    Curr Opin Hematol; 2010 Mar; 17(2):117-24. PubMed ID: 20071982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
    Cross NC; Reiter A
    Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
    Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
    Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilia: secondary, clonal and idiopathic.
    Tefferi A; Patnaik MM; Pardanani A
    Br J Haematol; 2006 Jun; 133(5):468-92. PubMed ID: 16681635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
    Borbényi Z
    Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-5 and hypereosinophilic syndromes.
    Sutton SA; Assa'ad AH; Rothenberg ME
    Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
    Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P
    Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
    Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
    Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
    Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW
    J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
    Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
    Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
    [No Abstract]   [Full Text] [Related]  

  • 14. [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib].
    Verstappen MC; Mattijssen V; van der Reijden BA; van der Heijden AJ; Wahab PJ; de Vries RA
    Ned Tijdschr Geneeskd; 2006 May; 150(21):1188-92. PubMed ID: 16768284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
    Payne SM; Kovacs MJ
    Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypereosinophilic syndrome--difficult-to-catch diagnosis. Targeted molecular diagnostics and treatment now possible thanks to gene discovery].
    Jönsson S; Lewerin C; Jacobsson S; Wadenvik H
    Lakartidningen; 2006 Sep 6-12; 103(36):2556-9. PubMed ID: 17007200
    [No Abstract]   [Full Text] [Related]  

  • 17. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
    Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
    N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approaches to therapy of hypereosinophilic syndromes.
    Simon HU; Cools J
    Immunol Allergy Clin North Am; 2007 Aug; 27(3):519-27. PubMed ID: 17868862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
    Lierman E; Cools J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
    Sørensen AL; Larsen H
    Ugeskr Laeger; 2008 Jan; 170(4):254. PubMed ID: 18282461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.